Neuromyelitis Optica Spectrum Disorders clinical trials at University of California Health
2 in progress, 1 open to eligible people
A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder
open to eligible people ages 2-17
The objective of this study is to evaluate the safety and efficacy of eculizumab in pediatric participants (aged 2 to < 18 years) with relapsing neuromyelitis optica spectrum disorder (NMOSD).
Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
Sorry, not currently recruiting here
A Phase 2, open-label, multicenter study to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of inebilizumab in eligible pediatric participants 2 to < 18 years of age with recently active neuromyelitis optica spectrum disorder (NMOSD) who are seropositive for autoantibodies against aquaporin-4 (AQP4-immunoglobulin [Ig]G).
Our lead scientists for Neuromyelitis Optica Spectrum Disorders research studies include Jennifer Sharon Graves, MD, PhD.